The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and other causes of Thyrotoxicosis: A European perspective

Thyroid

Volumn 21, Issue 6, 2011, Pages 585-591

  Kahaly, George J ^a   Bartalena, Luigi ^b   Hegedüs, Laszlo ^c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; PROPYLTHIOURACIL; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THIAMAZOLE;

ABLATION THERAPY; ECHOGRAPHY; EUROPE; EVIDENCE BASED MEDICINE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; IODINE 131 UPTAKE TEST; MEDICAL SOCIETY; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RELAPSE; REVIEW; THYROTOXICOSIS; TOXIC GOITER; VASCULARIZATION;

ANTITHYROID AGENTS; GRAVES OPHTHALMOPATHY; HUMANS; HYPERTHYROIDISM; IODINE RADIOISOTOPES; PRACTICE GUIDELINES AS TOPIC; THYROID GLAND; THYROID HORMONES; THYROTOXICOSIS;

EID: 79958803525     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.2106.ed3     Document Type: Review

References (77)

1. ATA/AACE Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis; Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall R, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN 2011 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593-646.
2. Rivkees SA, Mattison DR 2009 Ending propylthiouracilinduced liver failure in children. N Engl J Med 360:1574-1575.
3. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J 2009 Management of Graves hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 160:1-8.
4. Emiliano AB, Governale L, Parks M, Cooper DS 2010. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 95:2227-2233.
5. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall- Taylor P, Marcocci C, Mourits MP, Perros P, Boborides K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European group on Graves orbitopathy (EUGOGO) on management of Graves orbitopathy. Thyroid 18:333-346. (Pubitemid 351415802)
6. Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorf J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Tö rring O, Wallin G, Ä sman P, Lundell G, Thyroid Study group of TT 96 2009 Thyroid-associated ophthalmopathy after treatment for Graves hyperthyroidism with antithyroid drugs or iodine. J Clin Endocrinol Metab 94:3700-3707.
7. Ponto KA, Zang S, Kahaly GJ 2010 The tale of radioiodine and Graves Orbitopathy. Thyroid 20:785-793.
8. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333-1337.
9. Thomusch O, Machens A, Sekulla CM, Ukkat J, Lippert H, Gastinger I, Dralle H 2000 Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg 24:1335-1341.
10. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedü s L, Vitti P; AACE/AME/ETA Task Force on Thyroid Nodules 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest 33 (Suppl. 5):1-50.
11. Biondi B, Cooper DS 2008 The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29:76-131. (Pubitemid 351252748)
12. Bogazzi F, Bartalena L, Brogioni S, Burelli A, Grasso L, DellUnto E, Manetti L, Martino E 1997 Color flow Doppler sonography rapidly differentiates type I and type II amiodarone- induced thyrotoxicosis. Thyroid 7:541-545. (Pubitemid 27371790)
13. Bogazzi F,Martino E, DellUnto E, Brogioni S,Cosci C,Aghini- Lombardi F, Ceccarelli C, Pinchera A, Bartalena L, Braverman LE 2003 Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 26:635-640. (Pubitemid 37270694)
14. Bogazzi F, Bartalena L, Martino E 2010 Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 95:2529-2535.
15. Loy M, Perra E, Melis A, Cianchetti ME, Piga M, Serra A, Pinna G, Mariotti S 2007 Color-flow Doppler sonography in the differential diagnosis and management of amiodaroneinduced thyrotoxicosis. Acta Radiol 48:628-634. (Pubitemid 47147755)
16. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A 2007 Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 92 (Suppl 8):1-47.
17. Laurberg P, Cerquiera C, Ovesen L, Rasmussen LB, Perrild H, Andersen S, Pedersen IB, Carle A 2010 Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res Clin Endocrinol Metab 24:13-27.
18. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M 1991 Differences and similarities in the diagnosis and treatment of Graves disease in Europe, Japan, and the United States. Thyroid 1:129-135.
19. Ljunggren JG, Törring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G 1998 Quality of life aspects and costs in treatment of Graves hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 8:653-659. (Pubitemid 28405151)
20. Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedu ̈s L, Bjorner JB, Feldt-Rasmussen U 2006 Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol 154:501-510.
21. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19: 1167-1214.
22. Vaidya B, Williams GR, Abraham P, Pearce SH 2008 Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol 68 :814-820 Epub 2007 Oct 31 (Pubitemid 351533433)
23. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O 2008 TSH-receptor autoimmunity in Graves disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69-75. (Pubitemid 351211042)
24. Hegedüs L, Smith TJ, Douglas RS, Nielsen CH 2011 Targeted biological therapies for Graves disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol 74:1-8.
25. Vitti P, Rago T, Mancusi F, Pallini S, Tonacchera M, Santini F, Chiovato L, Marcocci C, Pinchera A 1992 Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves disease. Acta Endocrinol 126:128-131.
26. Vitti P 2000 Grey scale thyroid ultrasonography in the evaluation of patients with Graves disease. Eur J Endocrinol 142:22-24. (Pubitemid 30094194)
27. Rago T, Chiovato L, Grasso L, Pinchera A, Vitti P 2001 Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dysfunction in apparently healthy subjects. J Endocrinol Invest 24:763-769. (Pubitemid 33120970)
28. Bennedbaek FN, Hegedus L 1997 The value of ultrasonography in the diagnosis and follow-up of subacute thyroiditis. Thyroid 7:45-50. (Pubitemid 27132896)
29. Park SY, Kim EK, Kim MJ, Kim BM, Oh KK, Hong SW, Park CS 2006 Ultrasonographic characteristics of subacute granulomatous thyroiditis. Korean J Radiol 7:229-234. (Pubitemid 44905080)
30. Cappelli C, Pirola I, DeMartino E, Agosti B, Delbarba A, Castellano M, Agabiti-Rosei EA 2007 The role of imaging in Graves disease: a cost-effectiveness analysis. Eur J Radiol 65:99-103.
31. Vitti P, Rago T, Mazzeo S, Brogioni S, Lampis M, De Liperi A, Bartolozzi C, Pinchera A, Martino E 1995 Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves disease from Hashimotos thyroiditis. J Endocrinol Invest 18:857-861. (Pubitemid 26064023)
32. Morosini PP, Simonella G, Mancini V, Argalia G, Lucarelli F, Montironi R, Diamanti L, Suraci V 1998 Color Doppler sonography patterns related to histological findings in Graves disease. Thyroid 8:577-582. (Pubitemid 28354909)
33. Kurita S, Sakurai M, Kita Y, Ota T, Ando H, Kaneko S, Takamura T 2005 Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis. Thyroid 15:1249-1252. (Pubitemid 41821758)
34. Hari Kumar KV, Pasupuleti V, Jayaraman M, Abhyuday V, Rayudu B R, Modi KD 2009 Role of thyroid Doppler in differential diagnosis of thyrotoxicosis. Endocr Pract 15:6-9.
35. Ota H, Amino N, Morita S, Kobayashi K, Kubota S, Fukata S, Kamiyama N, Miyauchi A 2007 Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves disease. Clin Endocrinol 67:41-45. (Pubitemid 46955437)
36. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G 2007 Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 17:223-228. (Pubitemid 46557370)
37. Sipos JA 2009 Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid 19:1363-1372.
38. Becker D, Bair HJ, Becker W, Günter E, Lohner W, Lerch S, Hahn EG 1997 Thyroid autonomy with color-coded imagedirected Doppler sonography: internal hypervascularization for the recognition of autonomous adenomas. J Clin Ultrasound 25:63-69. (Pubitemid 27058465)
39. Boi F, Loy M, Piga M, Serra A, Atzeni F, Mariotti S 2000 The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres. Eur J Endocrinol 143:339-346.
40. Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H 2000 The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 10:251-259. (Pubitemid 30202412)
41. Raber W, Gessl A, Nowotny P, Vierhapper H 2002 Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid 12:725-731. (Pubitemid 34913246)
42. Schiemann U, Gellner R, Riemann B, Schierbaum G, Menzel J, Domschke W, Hengst K 1999 Standardized grey scale ultrasonography in Graves disease: correlation to autoimmune activity. Eur J Endocrinol 141:332-336. (Pubitemid 29529484)
43. Baldini M, Orsatti A, Bonfanti MT, Castagnone D, Cantalamessa L 2005 Relationship between the sonographic appearance of the thyroid and the clinical course and autoimmune activity of Graves disease. J Clin Ultrasound 33:381-385. (Pubitemid 41540986)
44. Zingrillo M, DAloiso L, Ghiggi MR, Di Cerbo A, Chiodini I, Torlontano M, Liuzzi A 1996 Thyroid hypoechogenicity after methimazole withdrawal in Graves disease: a useful index for predicting recurrence? Clin Endocrinol 45:201-206. (Pubitemid 26278314)
45. Yeh HC, Futterweit W, Gilbert P 1996 Micronodulation: ultrasonographic sign of Hashimoto thyroiditis. J Ultrasound Med 15:813-819. (Pubitemid 26405023)
46. Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M, Cantalamessa L 1997 Thyroid vascularization by color doppler ultrasonography in Graves disease. Changes related to different phases and to the long-term outcome of the disease. Thyroid 7:823-828. (Pubitemid 28041654)
47. Castagnone D, Rivolta R, Rescalli S, Baldini MI, Tozzi R, Cantalamessa L 1996 Color Doppler sonography in Graves disease: value in assessing activity of disease and predicting outcome. AJR Am J Roentgenol 166:203-207. (Pubitemid 26010251)
48. Ueda M, Inaba M, Kumeda Y, Nagasaki T, Hiura Y, Tahara H, Onoda N, Ishikawa T, Nishizawa Y 2005 The significance of thyroid blood flow at the inferior thyroid artery as a predictor for early Graves disease relapse. Clin Endocrinol 63:657-662. (Pubitemid 41779639)
49. Uchida T, Takeno K, Goto M, Kanno R, Kubo S, Takahashi S, Azuma K, Sakai K, Fujitani Y, Hirose T, Kawamori R, Watada H 2010 Superior thyroid artery mean peak systolic velocity for the diagnosis of thyrotoxicosis in Japanese patients. Endocr J 57:439-443.
50. Varsamidis K, Varsamidou E, Mavropoulos G 2000 Doppler ultrasonography in predicting relapse of hyperthyroidism in Graves disease. Acta Radiol 41:45-48.
51. Hari Kumar KV, Vamsikrishna P, Verma A, Muthukrishnan J, Meena U, Modi KD 2008 Evaluation of thyrotoxicosis during pregnancy with color flow Doppler sonography. Int J Gynaecol Obstet 102:152-155.
52. Schott M, Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, Golla R, Graeber C, van Helden J, Inomata K, Jarausch J, Kratzsch J, Miyazaki N, Moreno MA, Murakami T, Roth HJ, Stock W, Noh JY, Scherbaum WA, Mann K 2009 Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves disease (GD): an international multicentre trial. Clin Endocrinol 71:566-573.
53. Hermsen D, Broecker-Preuss M, Casati M, Mas JC, Eckstein A, Gassner D, van Helden J, Inomata K, Jarausch J, Kratzsch J, Mann K, Miyazaki N, Navarro Moreno MA, Murakami T, Roth HJ, Noh JY, Scherbaum WA, Schott M 2009 Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin Chim Acta 401:84-89.
54. Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ 2010 Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 162:438-446.
55. Lytton SD, Kahaly GJ 2010 Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev 10:116-122.
56. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ 2010 A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves orbitopathy J Clin Endocrinol Metab 95:2123-2131.
57. Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly GJ 2010 A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 20:851-856.
58. Okosieme OE, Chan D, Price SA, Lazarus JH, Premawardhana LDKE 2010 The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol 72:122-127.
59. Torizuka T, Kasagi K, Hatabu H, Misaki T, Iida Y, Konishi J, Endo K 1993 Clinical diagnostic potentials of thyroid ultrasonography and scintigraphy: an evaluation. Endocr J 40: 329-36. (Pubitemid 23280074)
60. Sarkar SD 2006 Benign thyroid disease: what is the role of nuclear medicine? Semin Nucl Med 36:185-93. (Pubitemid 43817849)
61. Bogazzi F, Vitti P 2008 Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nature Rev Endocrinol 4:70-71. (Pubitemid 351156882)
62. Bartalena L, Tanda ML 2009 Clinical practice. Graves ophthalmopathy. N Engl J Med 360:994-1001.
63. Bahn RS 2010 Graves ophthalmopathy. N Engl J Med 362: 726-738.
64. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199. (Pubitemid 32275594)
65. Kahaly GJ 2010 Management of moderately severe Graves orbitopathy. In: Wiersinga WM, Kahaly GJ (eds) Graves Orbitopathy. A Multidisciplinary Approach-Questions and Answers, 2nd revised edition. Karger, Basel, pp 120-158.
66. Zang S, Ponto KA, Kahaly GJ 2011 Intravenous glucocorticoids for Graves orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320-332
67. Zang S, Kahaly GJ 2011 Steroids and the immune response in Graves orbitopathy. Immunol Endocr Metab Agents Med Chem 11: in press
68. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P, Hansen JM 1995 Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves disease. J Intern Med 238: 491-497.
69. Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM 1999 Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 159:1364-1368. (Pubitemid 29293600)
70. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Müller-Brand J, Müller B 2007 Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomized controlled trials. BMJ 334:514.
71. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedüs L 2004 Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 89:4439-4444. (Pubitemid 39263740)
72. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, Grupe P, Andersen PB, Bastholt L, Hegedüs L 2006 Stimulation with 0.3- mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 166:1476-1482. (Pubitemid 44125866)
73. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, Grupe P, Andersen PB, Bastholt L, Hegedüs L 2007 Improvement of goiter volume reduction after 0.3mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 92:3424-3428. (Pubitemid 47435314)
74. Fast S, Hegedüs L, Grupe P, Nielsen VE, Bluhme C, Bastholt L, Bonnema SJ 2010 Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab 95:3719-3725.
75. Graf H, Fast S, Pacini F, Pinchera A, Leung M, Vaisman M, Reiners C, Wemeau JL, Huysmans D, Harper W, Driedger A, Noemberg de Souza H, Castagna MG, Antonangeli L, Braverman L, Corbo R, Düren C, Proust-Lemoine E, Edelbroek MA, Mariott C, Rachinsky I, Grupe P, Watt T, Magner J, Hegedüs L 2011 Modified-release human recombinant TSH (MRrhTSH) augments the effect of 131I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 96:1368-1376.
76. Hegedüs L 2009 Therapy: a new nonsurgical therapy option for benign thyroid nodules. Nat Rev Endocrinol 9:476-478.
77. Døssing H, Bennedbaek FN, Bonnema SJ, Grupe P, Hegedüs L 2007 Randomized prospective study comparing a single radioiodine dose and a single laser therapy session in autonomously functioning thyroid nodules. Eur J Endocrinol 157:95-100. (Pubitemid 47162571)